JoAnn Lindenfeld

Oct 29, 2024 | healio.com | Erik Swain |Richard Smith |B. Hadley Wilson |JoAnn Lindenfeld

B. Hadley Wilson, MD, FACC The key message here is that it does appear beneficial to consider doing TAVR on patients with moderate aortic stenosis and HFrEF. Two reasons that came out were that the TAVR group did better on the KCCQ score and reported symptomatic improvements, and that in the surveillance group, by 2 to 3 years, the majority of patients either underwent TAVR or expired.

Mar 24, 2023 | healio.com | Erik Swain |Richard Smith |JoAnn Lindenfeld

Source/Disclosures Source: Lindenfeld J, et al. Featured Abstracts. Presented at: Technology and Heart Failure Therapeutics; March 20-22, 2023; Boston. Disclosures: Lindenfeld reports receiving research funding from AstraZeneca and Volumetrix and receiving consultant fees/honoraria from Abbott, Alleviant Medical, AstraZeneca, Axon, Biotronik, Boston Scientific, CVRx, Edwards Lifesciences, Medtronic, Merck, Vascular Dynamics and V-Wave.

Mar 12, 2023 | nejm.org | Gregg W. Stone |William T Abraham |JoAnn Lindenfeld |Paul A. Grayburn

AbstractBackgroundData from a 5-year follow-up of outcomes after transcatheter edge-to-edge repair of severe mitral regurgitation, as compared with outcomes after maximal doses of guideline-directed medical therapy alone, in patients with heart failure are now available. Methods Download a PDF of the Research Summary.